A WONDER drug which targets a faulty gene stops the spread of prostate cancer, a trial has shown.
Olaparib offers hope to 4,000 British men in the advanced stages of the disease.
It is already used for women, such as actress Angelina Jolie, who are at greater risk of breast cancer from the BRCA gene mutation.
Now, early results from British drugs giant AstraZeneca reveal it halted the spread of tumours in 387 men with advanced prostate cancer.
Dr David Montgomery, from Prostate Cancer UK, said: “If the final results are as impressive as the early release implies, this could make a huge difference for men.”
Olaparib, right, is taken as a daily pill and works by stopping cancer cells repairing themselves.
Previous trials have shown it was effective for four in five advanced prostate cancer patients who have the faulty gene.
The latest results are so promising researchers think it will be available on the NHS by 2021, the first precision treatment for prostate cancer.
Professor Johann de Bono said: “We eagerly await the final analysis of the trial.” Every year 47,000 UK men get prostate cancer, 11,000 die.
GOT a story? Ring The Sun on 0207 782 4104 or WHATSAPP on 07423720250 or email firstname.lastname@example.org.